Seelos Therapeutics Performance
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Seelos Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Seelos Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent technical and fundamental indicators, Seelos Therapeutics is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 15.5 M |
Seelos |
Seelos Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Seelos Therapeutics on November 27, 2024 and sell it today you would earn a total of 100.00 from holding Seelos Therapeutics or generate -100.0% return on investment over 90 days. Seelos Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Seelos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Seelos Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Seelos Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Seelos Therapeutics, and traders can use it to determine the average amount a Seelos Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SEEL |
Based on monthly moving average Seelos Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Seelos Therapeutics by adding Seelos Therapeutics to a well-diversified portfolio.
Seelos Therapeutics Fundamentals Growth
Seelos OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Seelos Therapeutics, and Seelos Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Seelos OTC Stock performance.
| Return On Equity | -5.84 | |||
| Return On Asset | -2.61 | |||
| Profit Margin | 2.03 % | |||
| Operating Margin | (8.35) % | |||
| Current Valuation | 10.45 M | |||
| Shares Outstanding | 581 K | |||
| Price To Book | 15.10 X | |||
| Price To Sales | 0.37 X | |||
| Revenue | 2.2 M | |||
| EBITDA | (40.44 M) | |||
| Cash And Equivalents | 41.25 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 14.23 M | |||
| Debt To Equity | 0.73 % | |||
| Book Value Per Share | (135.50) X | |||
| Cash Flow From Operations | (23.91 M) | |||
| Earnings Per Share | 351.04 X | |||
| Total Asset | 5.42 M | |||
| Retained Earnings | (252.63 M) | |||
Things to note about Seelos Therapeutics performance evaluation
Checking the ongoing alerts about Seelos Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Seelos Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Seelos Therapeutics is not yet fully synchronised with the market data | |
| Seelos Therapeutics has some characteristics of a very speculative penny stock | |
| Seelos Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.2 M. Net Loss for the year was (37.88 M) with loss before overhead, payroll, taxes, and interest of (46.65 M). | |
| Seelos Therapeutics currently holds about 41.25 M in cash with (23.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. |
- Analyzing Seelos Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Seelos Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Seelos Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Seelos Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Seelos Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Seelos Therapeutics' otc stock. These opinions can provide insight into Seelos Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |